Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 21, 2015; 21(39): 11034-11043
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11034
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11034
Table 1 World Health Organization classification posttransplant lymphoproliferative disorder
Early lesions | Polymorphic PTLD | Monomorphic PTLD | |
Underlying architecture | (Partially) preserved | Destructed | Destructed |
Cells | Plasma cells, small lymphocytes and immunoblasts | Complete spectrum of B cell maturation | Fulfill criteria for lymphoma |
Immunohistochemistry | No diagnostic value | Mixture of B and T cells | Most cases CD20 positive |
EBV | 100% | > 90% | +/- 70% |
Clonality | In most cases polyclonal | Variable | Monoclonal |
Oncogenic mutations | No | Variable (BCL6) | Oncogenes (N-Ras, c-MYC,…) and tumor suppressor genes (p53,…) |
Table 2 Ann Arbor staging system for lymphoproliferative disorders
Stage I | Involvement of a single lymph node region (I) or one extralymphatic site (IE) |
Stage II | Involvement of two or more lymph node regions, at the same side of the diaphragm (II) or local extralymphatic extension plus one or more lymph node regions at the same side of the diaphragm (IIE) |
Stage III | Involvement of lymph node regions on both sides of diaphragm (III) which may include the spleen (IIIS) or accompanied by local extralymphatic extension (IIIE) or both (IIIES) |
Stage IV | Diffuse or disseminated involvement of one or more extralymphatic organs or sites, with or without associated lymphatic involvement |
- Citation: Dierickx D, Cardinaels N. Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? World J Gastroenterol 2015; 21(39): 11034-11043
- URL: https://www.wjgnet.com/1007-9327/full/v21/i39/11034.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i39.11034